BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it has received official notice from the Hong Kong Intellectual Property Department granting a patent using Tß4, analogues, isoforms and derivatives to accelerate corneal wound healing and reverse or inhibit eye degeneration. The patent claims are based on a significant body of data supporting the use of Tß4 for wound healing of the cornea and other areas in and around the eye.
